自拟健脾除积方联合信迪利单抗及化疗对晚期非小细胞肺癌患者的影响

Effects of self-designed Jianpi Chuji formula combined with sintilimab and chemotherapy on patients with advanced non-small cell lung cancer

目的:探讨自拟健脾除积方联合信迪利单抗及化疗对晚期非小细胞肺癌患者疾病控制率、中医症候积分及不良反应的影响。方法:选取2020年10月—2022年10月在我院就诊的102例晚期非小细胞肺癌患者,随机分为观察组和对照组,每组各51例,对照组在吉西他滨+顺铂化疗的基础上给予信迪利单抗,观察组在对照组基础上联合自拟健脾除积方治疗。比较两组患者临床疗效、治疗前后中医症候积分、肿瘤标志物水平及不良反应。结果:观察组有效率和疾病控制率明显高于对照组(P<0.05);观察组和对照组治疗后中医症候积分均显著低于治疗前;治疗后,观察组中医症候积分显著低于对照组(P<0.05)。两组治疗后血清铁蛋白(SF)、鳞状细胞癌抗原(SCCA)及癌胚抗原(CEA)水平均显著低于同组治疗前,观察组SF、SCCA、CEA水平均显著低于对照组。观察组白细胞计数减少、恶心、呕吐症状总发生率显著低于对照组(P<0.05)。结论:自拟健脾除积方联合信迪利单抗对晚期非小细胞肺癌患者治疗效果较好,可改善患者中医症候,具有较高的安全性。

Objective To explore the effects of self-designed Jianpi Chuji formula combined with sintilimab and chemotherapy on disease control rate,traditional Chinese medicine syndrome score,and untoward reactions in patients with advanced non-small cell lung cancer.Methods From October 2020 to October 2022,102 patients with advanced non-small cell lung cancer accepted by our hospital were randomly separated into an observation group and a reference group,with 51 patients in each group,the reference group was given sintilimab,while the observation group was treated with a combination of self-designed Jianpi Chuji formula based on reference group.The clinical efficacy,the TCM symptom scores,tumor marker levels before and after treatment,and untoward reactions were compared between the two groups.Results The effective rate(47.06%)and disease control rate(78.43%)of the observation group were obviously higher than those of the reference group(P<0.05).After treatment,the TCM symptom scores in the observation group were obviously lower than those in the reference group(P<0.05).After treatment,the levels of serum ferritin(SF),squamous cell carcinoma antigen(SCCA),and carcinoembryonic antigen(CEA)in both groups were obviously lower than those in the same group before treatment,the levels of SF,SCCA,and CEA in the observation group were obviously lower than those in the reference group.The total incidence of reduced white blood cell count,nausea,and vomiting symptoms in the observation group was obviously lower than that in the reference group(P<0.05).Conclusion The combination of self-designed Jianpi Quji formula and sintilimab has a good therapeutic effect on advanced non-small cell lung cancer patients,can improve their traditional Chinese medicine symptoms,and has high safety.